

1647

In re Application of: GRONHOJ-LARSEN, et al
Serial No.: 09/101,825
Filed: July 17, 1998
For: SYNTHETIC IL-10 ANALOGUES



Art Unit: 1647
Examiner: HAMUD, F.
Washington, D.C.
Atty.'s Docket: GRONHOJ-LARSEN-2
Date: July 11, 2001

RECEIVED

JUL 17 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

TECH CENTER 1600/2900

Transmitted herewith is an [XX] Amendment [XX] Osman (1998), Exhibits A-C, Larsen (USP 6,159,937) in the above-identified application.

- ☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☐ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate		Additional Fee
Total	49	Minus	55	0		x 9	\$	x18	\$
Indep.	2	Minus	4	0		x40	\$	x80	\$
First Presentation of Multiple Dependent Claim						135	\$	+270	\$
TOTAL ADDITIONAL CLAIMS FEE							\$	Total	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
- ☐ Second - \$195.00
- ☐ Third - \$445.00
- ☐ Fourth - \$695.00

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
- ☐ Second - \$ 390.00
- [XX] Third - \$ 890.00
- ☐ Fourth - \$1390.00

☐ Less fees (\$) already paid for months extension of time on

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

☐ A check in the amount of \$ is attached (check no.).

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$890.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

By:
IVER P. COOPER
Registration No. 28,005



2018
Dint
7-18-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 17 2001

TECH CENTER 1600/2900

In re Application of:) Art Unit: 1646
GRONHOJ-LARSEN, et al.) Examiner: HAMUD, F.
Serial No.: 09/101,825) Washington, D.C.
Filed: July 17, 1998) July 11, 2001
For: SYNTHETIC IL-10 ANALOGUES) Docket No.: GRONHOJ-LARSEN=2

AMENDMENT UNDER RULE 1.115

Commissioner of Patents
Washington, D.C. 20231

S i r :


In response to the office action mailed January 30, 2001,
please enter the following amendments and remarks:

IN THE CLAIMS

Please cancel claims 42-46, 48, 54, 55, 56, 58, 60, 62, and
64.

Please amend claims 18 and 41 as follows:

E1 18 (twice amended). A non-naturally occurring polypeptide,
or a polypeptide in at least partially purified form, which is
six to 20 amino acids in length, and which comprises the
following sequence



wherein X_4 and X_5 are independently selected from the group
consisting of Met, Ile, Leu, Val, norvaline, norleucine,
methionine-S-oxide, N-methylvaline, N-methyl isoleucine, allo-
leucine, and their D-isomers;

X_6 is selected from the group consisting of Asn, Asp, Gln, Glu,
and their D-isomers,

X_A is L-Thr or D-Thr,

X_B is L-Lys, L-Orn, L-Dab, or one of their D-isomers, and

X_C is L-Arg or D-Arg,